1. Federation of State Medical Boards. Report and recommendations of the workgroup to study regenerative and stem cell therapy practices. 2018; https://www.fsmb.org/siteassets/advocacy/policies/fsmb-stem-cell-workgroup-report.pdf. Accessed 20 Apr 2023.
2. Fang WH, Vangsness CT Jr. Governmental regulations and increasing Food and Drug Administration oversight of regenerative medicine products: what’s new in 2020? Arthroscopy. 2020;36:2765–70.
3. U.S. Food and Drug Administration. Important patient and consumer information about regenerative medicine therapies. 2021; https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies. Accessed 20 Apr 2023.
4. Cook M, Richey A, Brafman DA, et al. Weighing up the evidence used by direct-to-consumer stem cell businesses. Stem Cell Rep. 2021;16:2852–60.
5. U.S. Food and Drug Administration. What does FDA regulate? 2022; https://www.fda.gov/about-fda/fda-basics/what-does-fda-regulate. Accessed 20 Apr 2023.